Veracyte (VCYT) Competitors $39.18 -1.87 (-4.56%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$39.45 +0.27 (+0.69%) As of 02/21/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VCYT vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, LFST, PRVA, CON, and TDOCShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), LifeStance Health Group (LFST), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry. Veracyte vs. Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners LifeStance Health Group Privia Health Group Concentra Group Holdings Parent Teladoc Health Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Do analysts rate GH or VCYT? Guardant Health presently has a consensus target price of $44.78, indicating a potential upside of 4.45%. Veracyte has a consensus target price of $42.00, indicating a potential upside of 7.20%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Guardant Health 0 Sell rating(s) 0 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 3.00Veracyte 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals and insiders hold more shares of GH or VCYT? 92.6% of Guardant Health shares are owned by institutional investors. 5.5% of Guardant Health shares are owned by company insiders. Comparatively, 1.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GH or VCYT more profitable? Veracyte has a net margin of -2.18% compared to Guardant Health's net margin of -74.02%. Veracyte's return on equity of 3.02% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Guardant Health-74.02% -1,200.44% -29.88% Veracyte -2.18%3.02%2.80% Does the MarketBeat Community favor GH or VCYT? Veracyte received 156 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 72.91% of users gave Veracyte an outperform vote while only 70.59% of users gave Guardant Health an outperform vote. CompanyUnderperformOutperformGuardant HealthOutperform Votes28870.59% Underperform Votes12029.41% VeracyteOutperform Votes44472.91% Underperform Votes16527.09% Which has more risk & volatility, GH or VCYT? Guardant Health has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Does the media favor GH or VCYT? In the previous week, Guardant Health had 11 more articles in the media than Veracyte. MarketBeat recorded 21 mentions for Guardant Health and 10 mentions for Veracyte. Veracyte's average media sentiment score of 0.57 beat Guardant Health's score of 0.54 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Veracyte 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, GH or VCYT? Veracyte has lower revenue, but higher earnings than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGuardant Health$563.95M9.39-$479.45M-$4.24-10.11Veracyte$361.05M8.41-$74.40M-$0.15-261.20 SummaryVeracyte beats Guardant Health on 10 of the 18 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.04B$3.11B$5.77B$8.98BDividend YieldN/A20.51%4.78%3.85%P/E Ratio-261.2015.6226.4618.82Price / Sales8.41173.06453.2580.30Price / Cash453.71387.2444.0437.47Price / Book2.744.847.634.64Net Income-$74.40M-$22.21M$3.18B$245.69M7 Day Performance-4.69%-4.33%-1.91%-2.66%1 Month Performance-8.99%-2.39%-0.19%-2.15%1 Year Performance60.97%13.74%16.70%12.90% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte2.9157 of 5 stars$39.18-4.6%$42.00+7.2%+59.7%$3.18B$361.05M-261.20790Analyst DowngradeNews CoverageGHGuardant Health4.2446 of 5 stars$48.12+2.4%$42.63-11.4%+89.2%$5.95B$563.95M-11.351,779Earnings ReportAnalyst ForecastNews CoverageGap UpOPCHOption Care Health4.0316 of 5 stars$31.46-1.1%$32.25+2.5%-4.1%$5.35B$4.30B26.447,802Positive NewsRDNTRadNet3.9109 of 5 stars$61.33-1.9%$75.50+23.1%+54.4%$4.54B$1.62B-876.0210,288BTSGBrightSpring Health Services1.7615 of 5 stars$22.05-0.1%$19.42-11.9%+93.7%$3.84B$10.59B-84.8135,000SHCSotera Health2.1625 of 5 stars$13.48+0.4%$16.08+19.3%-17.6%$3.82B$1.05B53.923,000Analyst ForecastNews CoverageNegative NewsSGRYSurgery Partners3.0848 of 5 stars$25.87+0.3%$36.56+41.3%-23.0%$3.29B$2.74B-53.9013,500LFSTLifeStance Health Group1.5331 of 5 stars$7.97-0.3%$8.70+9.2%+22.0%$3.05B$1.21B-30.659,325Upcoming EarningsNews CoveragePositive NewsPRVAPrivia Health Group3.2393 of 5 stars$25.24+1.5%$24.94-1.2%+20.0%$3.03B$1.72B252.431,102News CoverageCONConcentra Group Holdings ParentN/A$22.69-0.6%$28.63+26.1%N/A$2.89B$1.84B0.0011,000Positive NewsTDOCTeladoc Health2.0385 of 5 stars$14.36+6.3%$12.08-15.9%-26.4%$2.47B$2.60B-2.495,600Analyst ForecastNews CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies Guardant Health Competitors Option Care Health Competitors RadNet Competitors BrightSpring Health Services Competitors Sotera Health Competitors Surgery Partners Competitors LifeStance Health Group Competitors Privia Health Group Competitors Concentra Group Holdings Parent Competitors Teladoc Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCYT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
